Adalimumab in active ulcerative colitis: a "real-life" observational study

Alessandro Armuzzi, Livia Biancone, Marco Daperno, Alessandra Coli, Daniela Pugliese, Vito Annese, Annalisa Aratari, Sandro Ardizzone, Paola Balestrieri, Fabrizio Bossa, Maria Cappello, Fabiana Castiglione, Michele Cicala, Silvio Danese, Renata D'Incà, Pietro Dulbecco, Giuseppe Feliciangeli, Walter Fries, Stefania Genise, Paolo GionchettiStefano Gozzi, Anna Kohn, Roberto Lorenzetti, Monica Milla, Sara Onali, Ambrogio Orlando, Luigi Giovanni Papparella, Sara Renna, Chiara Ricci, Fernando Rizzello, Raffaello Sostegni, Luisa Guidi, Claudio Papi

Research output: Contribution to journalArticle

55 Citations (Scopus)


The effectiveness of adalimumab in the treatment of ulcerative colitis is under debate. Although controlled trials have shown that adalimumab is significantly better than placebo, the absolute clinical benefit is modest. We report data on the effectiveness of adalimumab in a cohort of ulcerative colitis patients treated in 22 Italian centres.
Original languageEnglish
Pages (from-to)738-743
Number of pages6
JournalDigestive and Liver Disease
Publication statusPublished - 2013


  • Adalimumab
  • Ulcerative colitis
  • “Real-life” study


Dive into the research topics of 'Adalimumab in active ulcerative colitis: a "real-life" observational study'. Together they form a unique fingerprint.

Cite this